SequelSEC

4D Molecular Therapeutics, Inc. FDMT

Biological Products, (No Diagnostic Substances) · CIK 0001650648 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$85.21M
Fiscal year ended 2025-12-31
Operating income
-$159.55M
Fiscal year ended 2025-12-31
Free cash flow
-$109.62M
Fiscal year ended 2025-12-31

4D Molecular Therapeutics, Inc. (FDMT) reported revenue of $85.21M and net income of -$140.11M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from 4D Molecular Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

4D Molecular Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$85.21M$37.00K$20.72M$3.13M$18.04M$13.61M$6.99M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$159.55M-$187.84M-$112.87M-$110.03M-$71.33M-$56.66M-$50.76M
Net income-$140.11M-$160.87M-$100.84M-$107.49M-$71.32M-$56.69M-$49.31M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 57.93Mshares 53.94Mshares 39.13Mshares 32.35Mshares 27.73MUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0Unavailable
Diluted EPS$-2.42$-2.98$-2.58$-3.32$-2.57UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$49.06M$46.58M$36.49M$32.91M$28.01M$17.24M$13.90M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

4D Molecular Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$60.24M$149.34M$249.11M$52.35M$153.00M$276.73M$49.65M
Total assets$566.71M$560.38M$339.89M$261.85M$353.49M$288.33M$58.23M
Current assets$413.13M$434.93M$296.59M$220.51M$256.28M$282.66M$52.51M
Total liabilities$61.05M$49.78M$32.06M$30.51M$34.38M$31.94M$28.22M
Current liabilities$43.98M$29.15M$18.95M$15.73M$16.34M$16.74M$12.96M
Total equity incl. NCI$505.66M$510.61M$307.83M$231.34M$319.11M$256.39M-$72.97M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable$0$102.98M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable$0$47.00K$1.49M$978.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$11.16M$4.39M$3.52M$3.32M$4.76M$1.79M$1.74M

Cash flow

4D Molecular Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$109.08M-$134.58M-$75.79M-$86.68M-$69.13M-$50.91M-$36.71M
Capital expenditures$536.00K$3.79M$2.77M$11.54M$9.11M$1.00M$3.20M
Investing cash flow-$92.97M-$302.44M$115.72M-$17.05M-$172.68M-$1.00M-$3.20M
Financing cash flow$112.96M$337.25M$156.83M$3.08M$118.09M$278.98M-$2.20M
Net change in cash-$89.10M-$99.77M$196.76M-$100.65M-$123.72M$227.07M-$42.11M
Stock-based compensation$22.02M$26.12M$19.66M$17.12M$13.80M$4.98M$3.54M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$4.69M$4.65M$4.20M$2.40M$1.52M$1.44M$1.00M

Derived

4D Molecular Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow-$109.62M-$138.37M-$78.56M-$98.22M-$78.24M-$51.91M-$39.91M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-187.2%-507678.4%-544.6%-3516.5%-395.5%-416.3%-726.7%
FCF margin-128.6%-373975.7%-379.1%-3139.1%-433.8%-381.3%-571.3%
SBC / revenue25.8%70583.8%94.9%547.2%76.5%36.6%50.7%
Current ratio9.39x14.92x15.65x14.02x15.69x16.88x4.05x
Revenue YoY growth230194.6%-99.8%562.3%-82.7%32.5%94.8%Unavailable
Net margin-164.4%-434778.4%-486.6%-3435.4%-395.4%-416.5%-705.8%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue0.6%10232.4%13.4%368.7%50.5%7.3%45.8%
Long-term debt / equity0.00xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open FDMT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-18View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.